The University of Maryland School of Pharmacy and the University of Maryland Medical Center provide a one-year, PGY-2 residency training program in oncology pharmacy.

Please note the PGY-2 Oncology Pharmacy Residency Program has early committed for the 2020-21 training year.

This American Society of Health-System Pharmacists (ASHP)-accredited residency program combines patient care and clinical services, education and teaching, and research components to provide the resident with the expert skills and competencies necessary to obtain an academic or patient care role in the field of oncology pharmacy.

As part of its accreditation by ASHP, this program is committed to the following general purpose:

Postgraduate Year 2 (PGY2) pharmacy residency programs build on Doctor of Pharmacy (PharmD) education and Postgraduate Year 1 (PGY1) pharmacy residency programs to contribute to the development of clinical pharmacists in specialized areas of practice. PGY2 residencies provide residents with opportunities to function independently as practitioners by conceptualizing and integrating accumulated experience and knowledge and incorporating both into the provision of patient care that improves medication therapy. Residents who successfully complete an accredited PGY2 pharmacy residency should possess competencies that qualify them for clinical pharmacist and/or faculty positions and position them to be eligible for attainment of board certification in the specialized practice area (when board certification for the practice area exists).

Additionally, our program adheres to the "Goals and Objectives for a Post-Graduate Year Two Program in Oncology Pharmacy" set forth by ASHP. These goals and objectives can be found in the ASHP Residency Accreditation Regulations and Standards.

Learning Experiences:

The resident will provide patient care services as a member of an interprofessional team for the medical oncology, hematologic malignancies, and blood and marrow transplantation services. These rotations will be spent at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC). The UMGCCC is a National Cancer Institute (NCI) designated comprehensive cancer center, nationally known and internationally recognized as a leader in treating cancer. Its integrated, multidisciplinary approach to care combines specialized expertise, cutting-edge clinical research, and extensive support services for patients and their families.

Patient Care Rotations: Ten months are devoted to orientation and core experiences; two months are available for electives and/or additional core rotation learning experiences.

Core Rotations:

Orientation/Training 4 weeks
Medical Oncology 4 weeks
Hematologic Malignancies 8 weeks
Blood and Marrow Transplantation (BMT) 4 weeks
Investigational Drug Service 4 weeks
Pain and Palliative Care 4 weeks
Ambulatory Oncology (block) 4 weeks
Ambulatory Oncology (longitudinal; 1/2 day/week) 6-8 months*

Elective Rotations:

Pediatric Oncology 4 weeks
Infectious Disease Oncology 4 weeks
BMT II 4 weeks
Hematology and Medical Oncology Consults 4 weeks**
Others 4 weeks

*dependent on resident interest and on-site rotation availability

**2 weeks each


  • Clinical Research
  • Submission of research manuscript for publication and poster presentation
  • Medication Use Evaluation
  • Community Service Project
  • Formulary review, chemotherapy order and policy/guideline involvement
  • Chemotherapy Subcommittee of P&T and oncology medication safety meetings involvement


  • The resident is required to complete approximately 40 hours of teaching each semester.
  • Residents are appointed as clinical instructors at the University of Maryland School of Pharmacy.


  • The resident will work in the oncology pharmacy satellite every third Friday, Saturday and Sunday

In addition to these unique experiences, the resident is expected to participate in pharmacotherapy rounds, professional development lecture series, journal club, and case conference. More information about these specific activities is available on the general requirements page.

Number of Available Positions: 1

Qualifications: The resident must be a graduate of an accredited college of pharmacy with a minimum GPA of 3.0 (requirement waived if completed a pass/fail curriculum). The Doctor of Pharmacy (PharmD) degree and Maryland Pharmacy licensure are required. Residents must complete a PGY1 residency prior to starting.

Application Process:

Applicants must possess a Doctor of Pharmacy degree and have completed an ASHP-accredited residency in pharmacy practice. The resident will be required to become a licensed pharmacist in the state of Maryland.

Applications for this program will only be accepted through PhORCAS. Reference writers should use the standard reference template in PhORCAS.

Application requirements:

  • Letter of intent
  • Curriculum vitae
  • Letters of recommendation (3)
  • Official transcripts

International students and permanent residents should contact before applying.

Residents who match to this program will be required to come to Baltimore in advance of the July 1 start date for campus orientation; these orientation dates are not known until mid-spring. These sessions are typically offered on select Mondays in May and June.

The application deadline is January 1.

Program Director:

James A. Trovato, PharmD, MBA, BCOP, FASHP
Director, PGY-2 Oncology Pharmacy Residency Program Director
University of Maryland School of Pharmacy
20 North Pine Street, Room S448
Baltimore, MD 21201
Phone: (410) 706-2751
Fax: (410) 706-4725

Program Coordinator:

Alison Duffy, PharmD, BCOP
Coordinator, PGY-2 Oncology Pharmacy Residency Program Director
Associate Professor
University of Maryland School of Pharmacy
20 North Pine Street, Room N411
Baltimore, MD 21201
Phone: (410) 706-3274
Fax: (410) 706-4725